Back to Search
Start Over
Bivalent Human Papillomavirus (HPV) Vaccine Effectiveness Correlates With Phylogenetic Distance From HPV Vaccine Types 16 and 18.
- Source :
-
The Journal of infectious diseases [J Infect Dis] 2019 Aug 30; Vol. 220 (7), pp. 1141-1146. - Publication Year :
- 2019
-
Abstract
- To substantiate cross-protection reported across AS04-adjuvanted bivalent human papillomavirus (HPV) vaccine (2vHPV) studies, we reevaluated vaccine effectiveness against type-specific HPV positivity as a function of phylogenetic distance to vaccine target types HPV-16 and -18. We provide evidence of sustained cross-protection up to 8 years postvaccination in a high-risk population in the Netherlands. Moreover, our findings suggest that genomic distance better explains cross-protection than distance measures based on capsid antigens only. Taken together, 2vHPV is predicted to provide partial cross-protection against HPV-31, -33, -35, -45, -52, and possibly -58, that is, acknowledged oncogenic types with close phylogenetic relationships to HPV-16 or -18.<br /> (© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.)
- Subjects :
- Adolescent
Capsid Proteins genetics
Cross Protection genetics
Cross-Sectional Studies
Female
Genotype
Humans
Netherlands
Papanicolaou Test
Papillomavirus Vaccines immunology
Polymerase Chain Reaction
Treatment Outcome
Vaginal Smears
Young Adult
Human papillomavirus 16 genetics
Human papillomavirus 16 immunology
Human papillomavirus 18 genetics
Human papillomavirus 18 immunology
Papillomavirus Infections prevention & control
Papillomavirus Vaccines therapeutic use
Phylogeny
Subjects
Details
- Language :
- English
- ISSN :
- 1537-6613
- Volume :
- 220
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- The Journal of infectious diseases
- Publication Type :
- Academic Journal
- Accession number :
- 31165164
- Full Text :
- https://doi.org/10.1093/infdis/jiz280